Biomarin Pharmaceutical Inc. - Registered Shares
BMRN
Market Cap$14.62B
Close$
$97.25
25.4% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details
Target Price by Analysts
25.4% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details$6.40
91.7% downside
Current Fair Value
91.7% downsideOvervalued by 91.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.62 Billion |
|---|---|
| Enterprise Value | $14.66 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $1.07 |
| Beta | 0.52 |
| Outstanding Shares | 189,879,803 |
| Avg 30 Day Volume | 1,921,624 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 71.14 |
|---|---|
| PEG | 95.67 |
| Price to Sales | 5.97 |
| Price to Book Ratio | 2.98 |
| Enterprise Value to Revenue | 5.93 |
| Enterprise Value to EBIT | 82.71 |
| Enterprise Value to Net Income | 71 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
ESG Score
No data
About Biomarin Pharmaceutical Inc.
CEO: Jean-Jacques Bienaime